DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 1, 2006; DOI: 10.1124/dmd.105.009100


0090-9556/06/3406-943-949$20.00
DMD 34:943-949, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.009100v1
34/6/943    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dellinger, R. W.
Right arrow Articles by Lazarus, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dellinger, R. W.
Right arrow Articles by Lazarus, P.

IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) IN THE DETOXIFICATION OF POLYCYCLIC AROMATIC HYDROCARBONS: DECREASED GLUCURONIDATIVE ACTIVITY OF THE UGT1A10139LYS ISOFORM

Ryan W. Dellinger, Jia-Long Fang1, Gang Chen, Rebecca Weinberg, and Philip Lazarus

Cancer Prevention and Control Program, Division of Population Sciences and Cancer Prevention, Penn State Cancer Institute (R.W.D., J.-L.F., G.C., R.W., P.L.), and Departments of Pharmacology (R.W.D., P.L.) and Health Evaluation Sciences (G.C., P.L.), Penn State University College of Medicine, Hershey, Pennsylvania

UDP-glucuronosyltransferase 1A10 (UGT1A10) is an extrahepatic enzyme expressed in aerodigestive tract tissues that exhibits significant glucuronidation activity against the important procarcinogenic benzo(a)pyrene (BaP) metabolite, BaP-trans-7,8-dihydrodiol (BPD), and the UGT1A10 codon 139 (Glu>Lys) polymorphism was previously implicated in risk for orolaryngeal cancer by Elahi et al. in their 2003 study. To better assess the potential role of UGT1A10 in risk for tobacco-related cancers, the glucuronidation activity of UGT1A10 was compared with that of other known UGT enzymes against selected polycyclic aromatic hydrocarbons, and the effects of the codon 139 polymorphism on UGT1A10 function were examined in vitro. UGT1A10 exhibited considerably more glucuronidation activity as determined by Vmax/Km against 3-hydroxy (OH)-BaP, 7-OH-BaP, 9-OH-BaP, and 1-OH-pyrene than any other UGT1A family member. Although a kinetic comparison using Vmax could not be performed against family 2B UGTs, UGT1A10 exhibited a 1.7- to 254-fold lower Km than active family 2B UGTs against 3-OH-BaP, 7-OH-BaP, and 1-OH-pyrene. A significantly (p < 0.01) higher Vmax/Km was observed for homogenates from wild-type UGT1A10139Glu-overexpressing cells against all four BaP metabolites tested (3-OH-BaP, 7-OH-BaP, 9-OH-BaP, and BPD). A similarly significant (p < 0.05) increase in Vmax/Km was observed for homogenates from wild-type UGT1A10139Glu-overexpressing cells against 1-OH-pyrene. Significant differences in Km were observed for homogenates from wild-type UGT1A10139Glu-overexpressing cells against 1-OH-pyrene (p < 0.05) and 3-OH-BaP (p < 0.01). Reverse transcription-polymerase chain reaction of total lung RNA showed low levels of UGT1A10 expression in human lung tissue. Together, these studies implicate UGT1A10 as an important detoxifier of polycyclic aromatic hydrocarbons in humans and that the UGT1A10 codon 139 polymorphism may be an important determinant in risk for tobacco-related cancers.


Address correspondence to: Philip Lazarus, Penn State Cancer Institute, Penn State University College of Medicine, Room C3739D, MC-H069, 500 University Drive, Hershey, PA 17033. E-mail: plazarus{at}psu.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
G. Chen, R. W. Dellinger, D. Sun, T. E. Spratt, and P. Lazarus
Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10
Drug Metab. Dispos., May 1, 2008; 36(5): 824 - 830.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Sun, A. K. Sharma, R. W. Dellinger, A. S. Blevins-Primeau, R. M. Balliet, G. Chen, T. Boyiri, S. Amin, and P. Lazarus
Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases
Drug Metab. Dispos., November 1, 2007; 35(11): 2006 - 2014.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. W. Dellinger, G. Chen, A. S. Blevins-Primeau, J. Krzeminski, S. Amin, and P. Lazarus
Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10
Carcinogenesis, November 1, 2007; 28(11): 2412 - 2418.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Chen, A. S. Blevins-Primeau, R. W. Dellinger, J. E. Muscat, and P. Lazarus
Glucuronidation of Nicotine and Cotinine by UGT2B10: Loss of Function by the UGT2B10 Codon 67 (Asp>Tyr) Polymorphism
Cancer Res., October 1, 2007; 67(19): 9024 - 9029.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Gallagher, J. E. Muscat, A. N. Hicks, Y. Zheng, A.-M. Dyer, G. A. Chase, J. Richie, and P. Lazarus
The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 823 - 828.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.